November 6th, 2026Empire Forum 2026: Ambati on K8 phase 2 results in geographic atrophyJayakrishna Ambati, MD, discusses phase 2 K8 results in GA, its inflammasome mechanism, and dosing designed for convenience.Read more
November 5th, 2026Global Summit for Eye Health 2026: Turning pledges into eye careHunter Cherwek, MD, of Orbis discusses summit commitments, eye care workforce training, and AI in low-resource settings.Read more
October 30th, 2026OT Roundup: 3 FDA approvals, vorolanib insert miss, brepocitinib in uveitisVeeral Sheth, MD, breaks down the LUCIA wet AMD data, plus new AAO findings on GLP-1 agents and anti-VEGF treatment burden in DME.Read more
November 8th, 2026Training refractive surgeons and expanding access to eye surgeryIsa S. K. Mohammed, MD, on training refractive surgeons and why lasers make global access harder than for cataract surgery.Read more
October 29th, 2026Matching patients to PRK, LASIK, SMILE, or phakic IOLsIsa S. K. Mohammed, MD, explains how he matches patients to PRK, LASIK, SMILE, or phakic IOLs and how prior surgery affects IOLs.Read more
November 11th, 2026The One Thing: GA’s last frontier, the toll of ongoing care, back to glucose basics | Episode 6R. Ross Lakhanpal, MD, FACS, Anu Patel, MD, and Yasha S. Modi, MD, MHS, point to cell replacement in geographic atrophy, care burden, and glycemic control.Read more
November 11th, 2026VERONA: Katherine Talcott, MD, on early gains with a TKI insert in DMEKatherine Talcott, MD, discusses phase 2 VERONA findings on the vorolanib intravitreal insert in previously treated DMERead more
November 9th, 2026FDA aligns with VeonGen on pivotal phase 3 design for VG801 dual-AAV gene therapy in Stargardt diseaseVeonGen aligns with FDA on phase 3 design for VG801, a dual-AAV Stargardt gene therapy, after uncontrolled phase 1/2 BCVA gains.Read more